Potassium News and Research

RSS

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

27 Aug 2012

Diet and exercise help protect astronauts' bones in space

Eating the right diet and exercising hard in space helps protect International Space Station astronauts' bones, a finding that may help solve one of the key problems facing future explorers heading beyond low Earth orbit.

27 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

Coconut water really does deserve its popular reputation as Mother Nature's own sports drink

Coconut water really does deserve its popular reputation as Mother Nature's own sports drink, a new scientific analysis of the much-hyped natural beverage concluded here today at the 244th National Meeting & Exposition of the American Chemical Society (ACS).

21 Aug 2012

Researchers discover gene mutations linked to spinocerebellar ataxia

A global hunt for the cause of a crippling inherited nerve disorder has found its target. The discovery opens the door for better diagnosis and treatment of this particular disease - but also for better understanding of why nerves in the brain's movement-controlling center die, and how new DNA-mapping techniques can find the causes of other diseases that run in families.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Endocrine Society revises clinical practice guideline for management of thyroid dysfunction

The Endocrine Society has made revisions to its 2007 Clinical Practice Guideline (CPG) for management of thyroid disease during pregnancy and postpartum. The CPG provides recommendations for diagnosis and treatment of patients with thyroid-related medical issues just before and during pregnancy and in the postpartum interval.

12 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Medication reconciliation in hospitals: an interview with Dr. Leonard Feldman

Adverse drug effects are harms caused by the use of a medication. There are many different types of ADEs, including medication errors.

6 Aug 2012

Investigational drug shows promise against most severe form of congenital hyperinsulinism

A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high.

2 Aug 2012

New drug may be useful in treating long QT syndrome

Johns Hopkins researchers have discovered a new drug that may be useful in treating a heart rhythm condition called long QT syndrome.

1 Aug 2012

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.

31 Jul 2012

ATP1A3 gene mutations responsible for alternating hemiplegia of childhood

Alternating hemiplegia of childhood (AHC) is a rare disorder that usually begins in infancy, with intermittent episodes of paralysis and stiffness, first affecting one side of the body, then the other. Symptoms mysteriously appear and disappear, again and again, and affected children often experience dozens of episodes per week. As they get older, children fall progressively behind their peers in both intellectual abilities and motor skills, and more than half develop epilepsy.

31 Jul 2012

New drug shows promise for Long QT syndrome

Long QT syndrome, which results from genetic mutation or certain medications, can cause the heart to beat chaotically and the affected person to die suddenly. The chaotic heartbeat is due to abnormal electrical activity in the heart. In an electrocardiogram test, this abnormality appears as a wider-than-normal QT interval, a pattern of "hills" in a map of peaks and valleys corresponding to the heart contracting and relaxing.

30 Jul 2012

Potassium News and Research

Potassium-channel autoimmunity linked to chronic pain

Chronic nerve pain: an interview with Professor Sally Lawson

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Eplerenone shown to reduce cumulative heart failure hospitalisations

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Diet and exercise help protect astronauts' bones in space

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Coconut water really does deserve its popular reputation as Mother Nature's own sports drink

Researchers discover gene mutations linked to spinocerebellar ataxia

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Endocrine Society revises clinical practice guideline for management of thyroid dysfunction

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Medication reconciliation in hospitals: an interview with Dr. Leonard Feldman

Investigational drug shows promise against most severe form of congenital hyperinsulinism

New drug may be useful in treating long QT syndrome

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

ATP1A3 gene mutations responsible for alternating hemiplegia of childhood

New drug shows promise for Long QT syndrome

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News